Related Experiment Videos
Prulifloxacin as a trigger of myasthenia gravis
Marco Rossi1, Gaia Lusini, Alessia Biasella
1Department of Pharmacology Giorgio Segre, University of Siena, Siena, Italy. marcorss@alice.it
Abstract:
Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG). We present a case of MG following a treatment with prulifloxacin, a new broad-spectrum oral fluoroquinolone. Fluoroquinolones of any generation may interfere with neuromuscular transmission and should be avoided in patients with MG.
Insights
Fluoroquinolones, including prulifloxacin, can rarely worsen myasthenia gravis (MG). Patients with myasthenia gravis should avoid fluoroquinolone antibiotics due to potential neuromuscular transmission interference.
Area of Science:
- Neurology
- Pharmacology
Background:
- Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
- Fluoroquinolones are broad-spectrum antibiotics with known potential side effects.
Observation:
- A rare case of myasthenia gravis exacerbation occurred after treatment with prulifloxacin, a novel oral fluoroquinolone.
- This highlights a potential adverse drug reaction within the fluoroquinolone class.
Findings:
- Fluoroquinolones, regardless of generation, may disrupt normal neuromuscular transmission.
- Prulifloxacin use was temporally associated with a significant worsening of MG symptoms in this patient.
Implications:
- Clinicians should exercise caution when prescribing fluoroquinolones to patients diagnosed with myasthenia gravis.
- Avoiding fluoroquinolones in MG patients is recommended to prevent potential exacerbations and preserve neuromuscular function.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...